Synergistic Combination of Bioengineered MicroRNA and Chemotherapy Across High-Risk Neuroblastoma Subtypes
Despite intensive treatment, high-risk neuroblastoma (HRNB) remains a leading cause of cancer-related mortality in children. Current treatment paradigms include multimodal systemic treatments and multi-agent chemotherapy, which is limited by substantial acute and long-term toxicities. Platinum-based chemotherapy is a cornerstone of this treatment but is fraught with side effects and stands to…
We haven't written up this one. bioRxiv has the full story — the link below goes straight to it.
